!-- Google tag (gtag.js) -->

India-Made Cough Syrup Responsible for 66 Child Deaths in Gambia: WHO

India’s Central Drugs Standard Control Organisation was informed about the issue on 29 September and has already initiated an investigation into the matter.

October 6, 2022
India-Made Cough Syrup Responsible for 66 Child Deaths in Gambia: WHO
WHO Director-General Tedros Adhanom Ghebreyesus said that 66 child deaths are “potentially linked” to the presence of contaminants in the cough syrups.
IMAGE SOURCE: FABRICE COFFRINI/AFP

The World Health Organisation (WHO) issued an alert saying four “substandard” cough syrups manufactured by India-based Maiden Pharmaceuticals Ltd. are likely responsible for the deaths of 66 children from acute kidney issues in the Gambia. 

The WHO said that four Indian products – Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup, and Magrip N Cold Syrup – “fail to meet either quality standards or specification and are, therefore, out of specification,” noting that the children died between three and five days after consuming the products. 

All four products are manufactured by Haryana’s Maiden Pharmaceuticals Limited, which has not provided the WHO with any guarantees on the safety or quality of the medicines.

Laboratory analysis of the samples showed that the medicines contain “unacceptable amounts of diethylene glycol and ethylene glycol as contaminants.”  The chemicals have several “toxic effects” that can cause acute kidney injury and even death in certain instances.

Keeping this in mind, the WHO determined the four products to be “unsafe,” particularly for children, and warned against the use of the medicines until they are approved by the relevant National Regulatory Authorities.

The Organisation called on countries to increase “surveillance and diligence within the supply chains of countries and regions” that could be using these products. Furthermore, it urged countries to report the presence of the substandard medicines within their borders.

While there has been no proven link between the 66 child deaths and the medicines, WHO Director-General Tedros Adhanom Ghebreyesus said that the contents of the cough syrups are “potentially linked with acute kidney injuries and 66 deaths among children.”

He added that the organisation is investigating the incident in collaboration with the pharmaceutical company and Indian regulatory authorities. 

According to sources cited by Indian Express, India’s Central Drugs Standard Control Organisation was informed about the issue on 29 September and has already initiated an investigation into the matter. In addition, the Haryana regulatory body confirmed that Maiden Pharmaceutical produced the medicines. It further clarified that the drugs had only been exported to the Gambia.

However, Indian official sources cited by BBC raised concern that WHO has not established a “causal relation to death with the medical products in question.”

In addition, the WHO has not yet provided the Indian authorities with details of the product or photos confirming the manufacturer of the medicines.

India has been previously lauded as the “pharmacy of the world,” as it is responsible for one-third of the world’s medicines, a majority of which are generic drugs. The low-cost medicines have provided relief to mutiple poor countries. In fact, Maiden Pharmaceuticals exports medicines to Asia, Africa, and Latin America.

Concerningly, this is not the first time India-made cough syrups have attracted concern in the market. In 2020, 17 children in Jammu and Kashmir died after consuming another brand of cough syrup that also contained diethylene glycol. Similarly, three other children died in New Delhi in 2021 after consuming a cough syrup with dextromethorphan.